219 related articles for article (PubMed ID: 33439486)
21. Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy.
Kapur R
Br J Haematol; 2020 Sep; 190(6):817-818. PubMed ID: 32656765
[No Abstract] [Full Text] [Related]
22. Fostamatinib combined with TPO-RAs or steroids as a bridge to monotherapy or as time-limited continuous treatment in relapsed chronic ITP: A single-centre case series.
Passucci M; Laganà A; Donzelli L; Masucci C; Genoese A; Chistolini A; Baldacci E; Santoro C
Br J Haematol; 2024 May; 204(5):2129-2132. PubMed ID: 38563350
[No Abstract] [Full Text] [Related]
23. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
25. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials.
Ali MA; Anwar MY; Aiman W; Dhanesar G; Omar Z; Hamza M; Zafar M; Rengarajan HK; Maroules M
J Xenobiot; 2023 Jan; 13(1):29-41. PubMed ID: 36810430
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
Julia A; Kovaleva L; Loria S; Alberca I; Hernandez F; Sandoval V; Sierra J; Vidaller A; Ayguasanosa J; Carretero M
Transfus Med; 2009 Oct; 19(5):260-8. PubMed ID: 19747289
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children.
Ancona KG; Parker RI; Atlas MP; Prakash D
J Pediatr Hematol Oncol; 2002 Oct; 24(7):540-4. PubMed ID: 12368690
[TBL] [Abstract][Full Text] [Related]
29. Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia: studies in mouse models.
Martínez-Botía P; Meinders M; De Cuyper IM; Eble JA; Semple JW; Gutiérrez L
Blood Adv; 2022 Jun; 6(11):3529-3534. PubMed ID: 35298626
[TBL] [Abstract][Full Text] [Related]
30. Adult primary and secondary immune thrombocytopenic purpura: a comparative analysis of characteristics and clinical course.
Ayesh MH; Alawneh K; Khassawneh B; Khader Y; Kasasbeh A
Clin Appl Thromb Hemost; 2013 Jun; 19(3):327-30. PubMed ID: 22275396
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura.
Poudyal BS; Sapkota B; Shrestha GS; Thapalia S; Gyawali B; Tuladhar S
JNMA J Nepal Med Assoc; 2016; 55(203):16-21. PubMed ID: 27935917
[TBL] [Abstract][Full Text] [Related]
32. Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y
Am J Hematol; 2024 Feb; 99(2):E55-E59. PubMed ID: 38165064
[No Abstract] [Full Text] [Related]
33. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
34. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Scott IC; Scott DL
Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
[TBL] [Abstract][Full Text] [Related]
35. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
37. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.
Cooper N; Altomare I; Thomas MR; Nicolson PLR; Watson SP; Markovtsov V; Todd LK; Masuda E; Bussel JB
Ther Adv Hematol; 2021; 12():20406207211010875. PubMed ID: 33995988
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
Tungjitviboonkun S; Bumrungratanayos N; Jitwimungsanon J; Kheamakulvanich T; Siramongkholkarn S
Ann Hematol; 2024 Jun; ():. PubMed ID: 38856778
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
40. Increased thrombopoietin levels in idiopathic thrombocytopenic purpura patients with a poor response to steroid therapy.
Sakane Y; Wada H; Kazuyo H; Shimura M; Nakasaki T; Katayama N; Nishikawa M; Deguchi K; Mori Y; Mori Y; Shiku H; Tahara T; Kato T
Blood Coagul Fibrinolysis; 1998 Jun; 9(4):315-21. PubMed ID: 9690802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
